[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560854":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":23,"responsibleParty":38,"collaborators":7,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":7,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":7,"studyType":53,"phases":7,"briefSummary":54,"conditions":55,"keywords":7,"overallStatus":57,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Perosphere Technologies Inc.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","Whole Blood Clotting Time","Comparator",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Peter Verhamme, Professor","CONTACT","3216343491","peter.verhamme@uzleuven.be",{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},"Sasha Bakhru, PhD","475 237-4178","s.bakhru@perospheretech.com",[24],{"facility":25,"status":7,"city":26,"state":7,"zip":7,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"UZ Leuven Hospital","Leuven","Belgium","BE",{"type":30,"coordinates":31},"Point",[32,33],4.70093,50.87959,{"lat":33,"lon":32},[36,37],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},{"name":20,"role":16,"phone":7,"phoneExt":7,"email":22},{"type":39,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100560854","evaluation-of-clinical-ranges-of-whole-blood-clotting-times-of-patients-on-anticoagulants-100560854",false,"NCT06582563","Evaluation of Clinical Ranges of Whole Blood Clotting Times of Patients on Anticoagulants","Study for Evaluation of Clinical Ranges of Whole Blood Clotting Times","Inclusion Criteria:\n\n* In general, study participants must:\n\n  1. Be informed of the nature of the study and provide written informed consent before any study-specific procedures are performed.\n  2. Be 18- to 80-years-of-age, inclusive, at time of consent.\n  3. Have suitable venous access for at least a single venipuncture.\n  4. Eligible patients on anticoagulants must have taken their prescribed anticoagulant regularly at least for one month prior to study participation for inclusion\n\nExclusion Criteria:\n\n* Eligible patients on anticoagulants must not:\n\n  1. Other than the condition for which a DOAC was prescribed , have a personal or family history of clotting disorder or hematologic abnormality, such as excessive bleeding, joint hematoma, thrombovascular disease, thrombocytopenia, or any chronic condition requiring treatment with transfusions.\n  2. Have a BMI\\> 40 or weight \\> 120kg.\n  3. Suffer from renal or hepatic insufficiency.\n  4. Suffer from any pathology that would contra-indicate in general DOAC medication.\n  5. Have a history of unexplained syncope.\n  6. Have a history within 6 months prior to Screening of peptic ulcer or gastrointestinal bleeding (including hematemesis, melena, or rectal bleeding).\n  7. Consume more than 5 cigarettes per day.\n  8. If female, have a history of excessive or dysfunctional uterine bleeding (unless the subject had a subsequent hysterectomy).\n  9. If female is pregnant, breastfeeding, or planning to become pregnant during study","ALL","18 Years","80 Years",{"count":51,"type":52},120,"ESTIMATED","OBSERVATIONAL","Whole blood clotting time measurements are to collect the clotting time ranges for DOAC-anticoagulated patients and assess their correlation with plasma drug levels (via anti-FXa assay).",[56],"Blood Coagulation Disorder","NOT_YET_RECRUITING","2024-10-03",{"date":60,"type":61},"2024-10-08","ACTUAL",{"date":63,"type":52},"2025-03-01",{"date":65,"type":52},"2025-08-30",{"name":5,"class":6},1]